公开(公告)号：US20220226259A1

公开(公告)日：2022-07-21

申请号：US17628415

申请日：2020-04-29

申请人： VIVACELL BIOTECHNOLOGY ESPAÑA S.L.

发明人： Jon PEÑARANDO SÁEZ ,  Juan Diego UNCITI BROCTETA ,  Eduardo MUÑOZ BLANCO

IPC分类号： A61K31/05 ,  A61P35/00 ,  A61K35/17 ,  A61K38/17 ,  A61K45/06

摘要： It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells.
As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.